Solvemed Group
With the primary focus in Parkinson’s disease, Solvemed Group leverages its proprietary machine learning technology to develop novel diagnostic-predictive digital biomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools.
Focus: Diagnostics and drug discovery platform
Team: Hugo Chrost and Michal Wlodarski
Website: https://www.solvemed.ai
See other Diagnostics organisations
-
iLoF is working to enable a new era of personalised medicine, by using AI and photonics to build a cloud-based ... -
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual ... -
Aglaris Ltd produce equipment to ensure cell and tissue culture is an easy, problem-free task. -
AKL Research & Development Ltd.'s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system.
Be part of SBC Catalyser Programme!
Spaces are limited to a maximum of 10 companies per cohort. Contact Marco to know more or to apply.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.